Prednisolone With PhenylephrinePrednefrin Forte

6.1 The PBAC recommended listing prednisolone with phenylephrine as a Restricted Benefit for severe eye inflammation following cataract surgery for patients who identify as Aboriginal or Torres Strait Islander. In making its recommendation, the PBAC took into consideration, among other matters, the high clinical need of the patient population and that the listing would likely be cost neutral to Government.PSD · Nov 2019

6.2 The PBAC noted that the requested listing is consistent with the indications approved by the Therapeutic Goods Administration (TGA).PSD · Nov 2019

5.3 The PBAC noted that the minor submission was put forward by the National Aboriginal Community Controlled Health Organisation (NACCHO), with letters of support from representatives of the following organisations:  Allergan (the manufacturer of Prednefrin Forte)  Inala Indigenous Health Service  Lions Outback Vision  Outback Eye Service  The Royal Australian and New Zealand College of Ophthalmologists  Vision 2020  IDEAS Van Partnerships LtdPSD · Nov 2019

5.4 The submission claimed that anti-inflammatory ophthalmologic treatment is routinely indicated for post cataract surgery and that this is particularly important for Aboriginal and Torres Strait Islander patients, who have a higher incidence of diabetic macula oedema when inflammation is not controlled. These complications lead to a reduction in consumer and community engagement with cataract surgery and therefore poorer health outcomes.PSD · Nov 2019